new contact lens

We have a new contact lens!

We have a new contact lens!

Something to watch: a potential treatment option for retinitis pigmentosa. Aldeyra Therapeutics announced that the FDA has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP). Tell me more. Dihydrofolate reductase is an enzyme involved in cellular replication and activation. Methotrexate, the active component of ADX-2191, is a dihydrofolate reductase inhibitor that has been used to treat cancer and autoimmune disease. In addition to RP, the FDA has granted orphan drug designation to ADX-2191 for the treatment of primary vitreoretinal lymphoma, a rare, aggressive, high-grade cancer. The drug also received orphan drug designation and fast track designation for the prevention of proliferative vitreoretinopathy, which is the leading cause of retinal reattachment surgery failure. Stay tuned. (via) WHAT YOUR PATIENT MIGHT ASK YOU Are there any new monthly contact lenses? Yes! TOTAL30 (Alcon) is the newest member of the Water Gradient family, designed…
Read More